This is the protocol for a review and there is no abstract. The objectives are as follows:, Our primary objective is to assess the efficacy and safety of Octreotide in the treatment of chylothorax in neonates., Our secondary objective is to perform subgroup analyses based on:, (1) gestation (preterm or term), (2) route of administration of Octreotide, (3) congenital or acquired chylothorax, (4) timing of introduction of Octreotide (< 7 days or >=7 days of diagnosis)